Sagent Pharmaceuticals, Inc. 4
4 · Sagent Pharmaceuticals, Inc. · Filed Sep 1, 2016
Insider Transaction Report
Form 4
Vivo Ventures V, LLC
10% Owner
Transactions
- Disposition from Tender
Common Stock
2016-08-29$21.75/sh−2,978,803$64,788,965→ 0 total(indirect: See footnote) - Disposition from Tender
Common Stock
2016-08-29$21.75/sh−34,961$760,402→ 0 total(indirect: See footnote)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were disposed of in a cash tender offer by Shepard Vision, Inc. to acquire common stock of Sagent Pharmaceuticals, Inc. in exchange for $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Consideration").
- [F2]Shares previously held of record by Vivo Ventures Fund V, L.P. ("Fund V") .Vivo Ventures V, LLC, the sole general partner of Fund V, may be deemed to be the beneficial owner of the shares held by Fund V. Vivo Ventures V, LLC hereby disclaims any beneficial ownership of any shares directly held by Fund V, except to the extent of its pecuniary interest therein.
- [F3]Shares previously held of record by Vivo Ventures V Affiliates Fund, L.P. ("V Affiliates Fund"). Vivo Ventures V, LLC, the sole general partner of V Affiliates Fund, may be deemed to be the beneficial owner of the shares held by V Affiliates Fund. Vivo Ventures V, LLC hereby disclaims any beneficial ownership of any shares directly held by V Affiliates Fund, except to the extent of its pecuniary interest therein.